Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
SMMT
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Sales Growth
YoY
Current
Estimates
Return on Equity
QoQ
Institutionnal Ownership
QoQ
Q1.23
N/A
-0.06
vs -0.22
Q2.23
N/A
-0.02
vs -0.17
Q3.23
N/A
-0.03
vs -0.14
Q4.23
N/A
-0.04
vs -0.07
Q1.24
N/A
-0.05
vs -0.06
Q2.24
N/A
-0.05
vs -0.02
Q3.24
N/A
-0.08
vs -0.03
Q4.24
N/A
-0.08
vs -0.04
Q1.25
N/A
-0.07
vs -0.05
Q2.25
N/A
-0.07
vs -0.05
Q3.22
-83%
220K vs 1.3M
Q4.22
-100%
705 vs 251K
Q1.23
-100%
NA vs 250K
Q2.23
NA
235K vs 235K
Q3.23
-100%
NA vs 220K
Q4.23
-33433%
-235000.00 vs 705
Q1.24
NA
NA vs NA
Q2.24
-100%
NA vs 235K
Q3.24
NA
NA vs NA
Q4.24
+100%
NA vs -235000
Q1.23
-406%
-4.06
vs -0.13
Q2.23
-12%
-0.12
vs -4.06
Q3.23
-21%
-0.21
vs -0.12
Q4.23
-47%
-0.47
vs -0.21
Q1.24
-98%
-0.98
vs -0.47
Q2.24
-31%
-0.31
vs -0.98
Q3.24
-13%
-0.13
vs -0.31
Q4.24
-16%
-0.16
vs -0.13
Q1.23
99
99
vs 62
60%
Q2.23
102
102
vs 99
3%
Q3.23
95
95
vs 102
-7%
Q4.23
98
98
vs 95
3%
Q1.24
107
107
vs 98
9%
Q2.24
134
134
vs 107
25%
Q3.24
192
192
vs 134
43%
Q4.24
227
227
vs 192
18%
benzinga.com
15 hours ago
benzinga.com
15 hours ago
businesswire.com
16 hours ago
Forecast
NaN%2025-Revenue
-306%2025-EPS
89%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
40.33(71.87%)
Number of analyst
3
Last analyst upgrade/downgrade
Citigroup
upgradePrevious: Neutral
2025-03-26
Now: Buy
Evercore ISI
initialisePrevious: Not converted
2025-03-12
Now: Outperform
Goldman Sachs
initialisePrevious: Not converted
2025-02-28
Now: Buy
Wells Fargo
initialisePrevious: Not converted
2024-12-11
Now: Overweight
Quote Panel
Key Metrics
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
NASDAQ
Unprofitable
Unprofitable
-13.23 ( -36.06%)
Pre-market 25.32$1.85 (7.88%)
Relative Strenght
98
Volume Buzz
594%
Earning Acce
No
Dist 52w H.
36%Relative Strength
SMMT
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
